Search

4 result(s) for 'author#"Patrick Dorn"' within BMC

1. Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment

   Cisplatin plus pemetrexed combination therapy is considered the standard treatment for patients with advanced, non-squamous, non-small-cell lung cancer (NSCLC). However, advanced NSCLC has a 5-year survival ra...

   Authors: Yanyun Gao, Patrick Dorn, Shengchen Liu, Haibin Deng, Sean R. R. Hall, Ren-Wang Peng, Ralph A. Schmid and Thomas M. Marti

   Citation: Cancer Cell International 2019 19:317

   Content type: Primary research

   Published on: 29 November 2019

   • View Full Text
   • View PDF

2. Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells

   Lung cancer causes the most cancer deaths worldwide, thus there is a urgent need to develop new treatment options. Concurrent chemoradiotherapy has become a common strategy for the treatment of non-resectable ...

   Authors: Patrick Dorn, Colin Charles Tièche, Ren-Wang Peng, Laurène Froment, Ralph Alexander Schmid and Thomas Michael Marti

   Citation: Cancer Cell International 2016 16:66

   Content type: Primary research

   Published on: 2 September 2016

   • View Full Text
   • View PDF

3. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT

   Lung cancer is the leading cause of cancer-related mortality, and new therapeutic options are urgently needed. Non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancers, with the c...

   Authors: Colin Charles Tièche, Ren-Wang Peng, Patrick Dorn, Laurène Froment, Ralph Alexander Schmid and Thomas Michael Marti

   Citation: BMC Cancer 2016 16:125

   Content type: Research article

   Published on: 19 February 2016

   • View Full Text
   • View PDF

4. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)

   Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is bel...

   Authors: Yanyun Gao, Philipp Zens, Min Su, Camila Anna Gemperli, Haitang Yang, Haibin Deng, Zhang Yang, Duo Xu, Sean R. R. Hall, Sabina Berezowska, Patrick Dorn, Ren-Wang Peng, Ralph Alexander Schmid, Wenxiang Wang and Thomas Michael Marti

   Citation: Journal of Experimental & Clinical Cancer Research 2021 40:138

   Content type: Research

   Published on: 19 April 2021

   • View Full Text
   • View PDF